Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry.

Ann Rheum Dis 2021 May 28

Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry.

Related Questions

What bDMARD would you choose for a patient with RA with high infection risk and inadequate response to cDMARDs?

Infection risk being primarily chronic venous stasis ulcers

New comment by at Hospital Perea ( November 15, 2022)

Excellent review.

Read more (1 Answer available)